上海医药:下属公司紫杉醇注射液获药品注册证书

财中社
Sep 28

9月28日,上海医药(601607/02607)发布公告,近日,公司下属上海金和生物制药有限公司收到国家药品监督管理局颁发的关于紫杉醇注射液的《药品注册证书》,该药品获得批准生产。  紫杉醇注射液适用于进展期卵巢癌的一线、后继治疗及淋巴结阳性的乳腺癌患者在含阿霉素标准方案联合化疗后的辅助治疗等。  截至本公告日,公司针对该药品已投入研发费用约451万元,IQVIA 数据库显示,2025年中国大陆...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10